The breakdown of myelin, the insulating layer around brain cells that supports brain function, is prevalent in a range of ...

Obexelimab almost completely prevented new inflammatory lesions visible on brain scans of adults with relapsing MS, per trial data.

Objective To examine the predictive value of central atrophy in early multiple sclerosis (MS) patients, for medium term clinical outcome. Methods In 54 patients with recently diagnosed MS, clinical ...

Key updates in disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) forum are reported ...

Authors say increases in disability were seen around age 50 years are likely due to other aging processes. HealthDay News — Menopause is not a leading factor for disability progression in women with ...

Abstract: Multiple Sclerosis (MS) is a long-term neurological condition that significantly impacts the spinal cord and brain. Diagnosis of MS is primarily conducted through various methods, with ...

Background The purpose of this study was to clarify the usefulness of the ‘hot cross bun’ sign (HCBS) as a diagnostic imaging marker in a large cohort of patients with multiple system atrophy (MSA) ...

The final, formatted version of the article will be published soon. Brain atrophy as assessed by magnetic resonance imaging (MRI) is a key measure of neurodegeneration and a predictor of disability ...

The New York Jets have seen injury added to insult after a Week 6 loss to the Denver Broncos in London. Garrett Wilson, the Jets' No. 1 wide receiver, has a knee injury, according to ESPN's Rich ...

Abstract: Multiple sclerosis causes progressive brain morphology alterations through myelin sheath damage, leading to diverse symptoms depending on the affected brain areas. Magnetic resonance imaging ...

After two years of treatment, natalizumab (NTZ) reduces the frequency of relapses and slows the progression of disability in relapsing‐remitting multiple sclerosis (RRMS) when compared with placebo ...